The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups

References

• Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta‑analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010). ▪▪ Largest meta-analysis of 26 randomized controlled statin trials showing that the magnitude of LDL cholesterol (LDL-C) lowering is related to cardiovascular event reduction.
   Google Scholar
• Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists’ (CTT) Collaborators efficacy and safety of cholesterol‑lowering treatment: prospective meta‑analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267–1278 (2005).
   Google Scholar
• Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A metaregression analysis. J. Am. Coll. Cardiol. 46(10), 1855–1862 (2005). ▪▪ Meta-analysis of 18 intervention trials assessing the relationship between LDL-C lowering with statin and nonstatin therapy with cardiovascular disease (CVD) risk reduction.
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002).
   Google Scholar
• Genest J, McPherson R, Frohlich J et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can. J. Cardiol. 25(10), 567–579 (2009).
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 44(3), 720–732 (2004).
   Google Scholar
• Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19), 2363–2372 (2006).
   Google Scholar
• Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(1), 3–46 (2011).
   Google Scholar
• Foody JM, Sajjan SG, Hu XH et al. Loss of early gains in low‑density lipoprotein cholesterol goal attainment among high‑risk patients. J. Clin. Lipidol. 4(2), 126–132 (2010).
   Google Scholar
• Nichols GA, Nag S, Chan W. Intensity of lipid‑lowering therapy and low‑density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am. Heart J. 154(3), 554–560 (2007).
   Google Scholar
• Caslake MJ, Packard CJ. Phenotypes, genotypes and response to statin therapy. Curr. Opin. Lipidol. 15(4), 387–392 (2004).
   Google Scholar
• Mangravite LM, Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. Curr. Opin. Mol. Ther. 10(6), 555–561 (2008).
   Google Scholar
• Cooper A, Nherera L, Calvert N et al. Clinical Guidelines and Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease. National Collaborating Centre for Primary Care and Royal College of General Practitioners, London, UK (2008).
   Google Scholar
• Cooper A , O’Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ 336(7655), 1246–1248 (2008).
   Google Scholar
• Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 223(1), 1–68 (2012).
   Google Scholar
• Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31(4), 811–822 (2008).
   Google Scholar
• Mosca L, Benjamin EJ, Berra K et al. Effectiveness‑based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. J. Am. Coll. Cardiol. 57(12), 1404–1423 (2011).
   Google Scholar
• National Institute for Health and Clinical Excellence. Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: the Identification and Management of Adults and Children with Familial Hypercholesterolaemia. National Institute for Health and Clinical Excellence, UK.
   Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am. J. Kidney Dis. 41(Suppl. 3), S1–S92 (2003).
   Google Scholar
• Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S18–S29 (2011).
   Google Scholar
• Lloyd‑Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3), e21–e181 (2009).
   Google Scholar
• Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta‑analysis. J. Am. Coll. Cardiol. 51(1), 37–45 (2008).
   Google Scholar
• Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta‑analysis. J. Gerontol. A Biol. Sci. Med. Sci. 62(8), 879–887 (2007).
   Google Scholar
• Cournot M, Cambou JP, Quentzel S, Danchin N. Key factors associated with the under‑prescription of statins in elderly coronary heart disease patients: results from the ELIAGE and ELICOEUR surveys. Int. J. Cardiol. 111(1), 12–18 (2006).
   Google Scholar
• Jellinger PS, Smith DA, Mehta AE et al. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr. Pract. 18(Suppl. 1), 1–78 (2012).
   Google Scholar
• Pasternak RC, Smith SC Jr, Bairey‑Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106(8), 1024–1028 (2002).
   Google Scholar
• Zocor® (simvastatin), prescribing information. Merck Sharp & Dohme Corp., NJ, USA (2012).
   Google Scholar
• Mevacor® (lovastatin), prescribing information. Merck Sharp & Dohme Corp., NJ, USA (2012).
   Google Scholar
• Lipitor®, prescribing information. Pfizer, NY, USA (2012).
   Google Scholar
• Chen YC, Chen YD, Li X et al. The HMG‑CoA reductase gene and lipid and lipoprotein levels: the multi‑ethnic study of atherosclerosis. Lipids 44(8), 733–743 (2009).
   Google Scholar
• Ferdinand KC, Clark LT, Watson KE et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African–American patients in a six‑week trial. Am. J. Cardiol. 97(2), 229–235 (2006).
   Google Scholar
• Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3‑hydroxyl‑3‑methylglutaryl coenzyme a reductase gene is associated with racial differences in low‑density lipoprotein cholesterol response to simvastatin treatment. Circulation 117(12), 1537–1544 (2008).
   Google Scholar
• Simon JA, Lin F, Hulley SB et al. Phenotypic predictors of response to simvastatin therapy among African‑Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am. J. Cardiol. 97(6), 843–850 (2006).
   Google Scholar
• Standards of medical care in diabetes – 2012. Diabetes Care 35(Suppl. 1), S11–S63 (2012).
   Google Scholar
• Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome – Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Ciculation 109, 433–438 (2004).
   Google Scholar
• Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109(4), 551–556 (2004).
   Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735–2752 (2005).
   Google Scholar
• Grundy SM. Low‑density lipoprotein, non‑high‑density lipoprotein, and apolipoprotein B as targets of lipid‑lowering therapy. Circulation 106(20), 2526–2529 (2002).
   Google Scholar
• Goldberg AC, Hopkins PN, Toth PP et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S1–S8 (2011).
   Google Scholar
• Watts GF, Sullivan DR, Poplawski N et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler. Suppl. 12(2), 221–263 (2011).
   Google Scholar
• Stefanutti C, Morozzi C, Di Giacomo S. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia. Curr. Med. Chem. 19(28), 4861–4868 (2012).
   Google Scholar
• Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255–2267 (2011). ▪ Assessed the effect of combination niacin plus simvastatin therapy versus simvastatin on HDL cholesterol raising and cardiovascular risk in patients with LDL-C <70 mg/dl goal.
   Google Scholar
• Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J. Am. Soc. Nephrol. 16(2), 489–495 (2005).
   Google Scholar
• Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 80(1), 17–28 (2011).
   Google Scholar
• Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y. Elevated non‑high‑density lipoprotein cholesterol (non‑HDL‑C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6(5), 1112–1120 (2011).
   Google Scholar
• Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease. Contrib. Nephrol. 171, 135–142 (2011). ▪ Describes the lipid abnormalities associated with metabolism of apoB and apoA lipoproteins in chronic kidney disease patients.
   Google Scholar
• Savarese G, Musella F, Volpe M, Paneni F, Perrone‑Filardi P. Effects of atorvastatin and rosuvastatin on renal function: a meta‑analysis. Int. J. Cardiol. pii: S0167‑5273(12)00621‑3 (2012).
   Google Scholar
• Wu Y, Wang Y, An C et al. Effects of rosuvastatin and atorvastatin on renal function: meta‑analysis. Circ. J. 76(5), 1259–1266 (2012).
   Google Scholar
• Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J. Am. Coll. Cardiol. 21(5), 1220–1225 (1993).
   Google Scholar
• Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. J. Am. Coll. Cardiol. 29(3), 630–634 (1997).
   Google Scholar
• Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 48(3), e1–e148 (2006).
   Google Scholar
• Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur. Heart J. 28(2), 230–268 (2007).
   Google Scholar
• Wierzbicki AS, Viljoen A, Chambers JB. Aortic stenosis and lipids: does intervention work? Curr. Opin. Cardiol. 25(4), 379–384 (2010).
   Google Scholar
• Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O’Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359(9312), 1125–1126 (2002).
   Google Scholar
• Rosenhek R, Rader F, Loho N et al. Statins but not angiotensin‑converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110(10), 1291–1295 (2004).
   Google Scholar
• Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104(18), 2205–2209 (2001).
   Google Scholar
• Cowell SJ, Newby DE, Prescott RJ et al. A randomized trial of intensive lipid‑lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352(23), 2389–2397 (2005).
   Google Scholar
• Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359(13), 1343–1356 (2008). ▪▪ The SEAS trial compared the effect of combination ezetimibe plus simvastatin on cardiovascular events in aortic stenosis patients.
   Google Scholar
• Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Circulation 121(2), 306‑U247 (2010).
   Google Scholar
• Davis HR Jr, Tershakovec AM, Tomassini JE, Musliner T. Intestinal sterol transporters and cholesterol absorption inhibition. Curr. Opin. Lipidol. 22(6), 467–478 (2011). ▪ Review of intestinal cholesterol transporters and cholesterol absorption inhibitors including ezetimibe, currently the only approved cholesterol absorption inhibitor.
   Google Scholar
• Toth PP, Catapano A, Tomassini JE, Tershakovec AM. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clin. Lipidol. 5(5), 655–684 (2010). ▪ Most recent updated review of the clinical efficacy and safety of ezetimibe in combination with statins.
   Google Scholar
• Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev. Cardiovasc. Ther. 6(4), 447–470 (2008).
   Google Scholar
• Tang W, Jia L, Ma Y et al. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann‑Pick C1‑Like 1 only in liver. Biochim. Biophys. Acta 1811(9), 549–555 (2011).
   Google Scholar
• Temel RE, Tang W, Ma Y et al. Hepatic Niemann‑Pick C1‑like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest 117(7), 1968–1978 (2007).
   Google Scholar
• Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long‑term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler. Thromb. Vasc. Biol. 20(5), 1340–1346 (2000).
   Google Scholar
• Nissinen MJ, Miettinen TE, Gylling H, Miettinen TA. Applicability of non‑cholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men. Nutr. Metab. Cardiovasc. Dis. 20(5), 308–316 (2010).
   Google Scholar
• Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe‑statin therapies on non‑cholesterol sterols in patients with primary hypercholesterolemia. Curr. Med. Res. Opin. 24(1), 249–259 (2008).
   Google Scholar
• Jakulj L, Vissers MN, Groen AK et al. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post‑hoc analysis of the ENHANCE trial. J. Lipid Res. 51(4), 755–762 (2010).
   Google Scholar
• Lakoski SG, Xu F, Vega GL et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J. Clin. Endocrinol. Metab. 95(2), 800–809 (2010).
   Google Scholar
• Vytorin®, precribing information. Merck Sharp & Dohme Corp., NJ, USA (2012).
   Google Scholar
• Zetia®, prescribing information. Merck Sharp & Dohme Corp., NJ, USA (2012).
   Google Scholar
• Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2125–2134 (2002).
   Google Scholar
• Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 91(4), 418–424 (2003).
   Google Scholar
• Melani L, Mills R, Hassman D et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double‑blind trial. Eur. Heart J. 24(8), 717–728 (2003).
   Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double‑blind trial. Circulation 107(19), 2409–2415 (2003).
   Google Scholar
• Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double‑blind, placebocontrolled trial. Mayo Clin. Proc. 79(5), 620–629 (2004).
   Google Scholar
• Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double‑blind, placebo‑controlled, factorial design study to evaluate the lipid‑altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther. 26(11), 1758–1773 (2004).
   Google Scholar
• Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co‑administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. 93(12), 1487–1494 (2004).
   Google Scholar
• Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose‑comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J. 149(3), 464–473 (2005).
   Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM et al. Lipid‑altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin. 22(10), 2041–2053 (2006).
   Google Scholar
• Feldman T, Koren M, Insull W Jr et al. Treatment of high‑risk patients with ezetimibe plus simvastatin co‑administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low‑density lipoprotein cholesterol goals. Am. J. Cardiol. 93(12), 1481–1486 (2004).
   Google Scholar
• Rodney RA, Sugimoto D, Wagman B et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African–American patients with primary hypercholesterolemia. J. Natl Med. Assoc. 98(5), 772–778 (2006).
   Google Scholar
• Goldberg RB, Guyton JR, Mazzone T et al. Ezetimibe/simvastatin vs atorvastatin in patients with Type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin. Proc. 81(12), 1579–1588 (2006).
   Google Scholar
• Robinson JG, Ballantyne CM, Grundy SM et al. Lipid‑altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am. J. Cardiol. 103(12), 1694–1702 (2009).
   Google Scholar
• Foody JM, Brown WV, Zieve F et al. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). Am. J. Cardiol. 106(9), 1255–1263 (2010).
   Google Scholar
• Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1084–1091 (2002).
   Google Scholar
• Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community‑based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add‑on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. 80(5), 587–595 (2005).
   Google Scholar
• Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL‑C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr. Med. Res. Opin. 21(4), 571–578 (2005).
   Google Scholar
• Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of co‑administering ezetimibe with on‑going simvastatin treatment on LDL‑C goal attainment in hypercholesterolemic patients with coronary heart disease. Int. J. Cardiol. 102(2), 327–332 (2005).
   Google Scholar
• Cruz‑Fernandez JM, Bedarida GV, Adgey J, Allen C, Johnson‑Levonas AO, Massaad R. Efficacy and safety of ezetimibe coadministered with ongoing atorvastatin therapy in achieving low‑density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int. J. Clin. Pract. 59(6), 619–627 (2005).
   Google Scholar
• Dobs AS, Guyton JR, McClusky D et al. Coadministration of ezetimibe with simvastatin. J. Am. Coll. Cardiol. 41, 227A (2003).
   Google Scholar
• Stein E, Stender S, Mata P et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co‑administered with atorvastatin. Am. Heart J. 148(3), 447–455 (2004).
   Google Scholar
• Gaudiani LM, Lewin A, Meneghini L et al. Efficacy and safety of ezetimibe co‑administered with simvastatin in thiazolidinedione‑treated Type 2 diabetic patients. Diabetes Obes. Metab. 7(1), 88–97 (2005).
   Google Scholar
• Conard SE, Bays HE, Leiter LA et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am. J. Cardiol. 102(11), 1489–1494 (2008).
   Google Scholar
• Leiter LA, Bays H, Conard S et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am. J. Cardiol. 102(11), 1495–1501 (2008).
   Google Scholar
• Zieve F, Wenger NK, Ben Yehuda O et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or = 65 years of age (from the zetia in the elderly [ZETELD] study). Am. J. Cardiol. 105(5), 656–663 (2010).
   Google Scholar
• Reckless JP, Henry P, Pomykaj T et al. Lipid‑altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int. J. Clin. Pract. 62(4), 539–554 (2008).
   Google Scholar
• Bays HE, Davidson MH, Massaad R et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus uptitration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am. J. Cardiol. 108(4), 523–530 (2011).
   Google Scholar
• Barrios V, Amabile N, Paganelli F et al. Lipid‑altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared with doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int. J. Clin. Pract. 59(12), 1377–1386 (2005).
   Google Scholar
• Constance C, Westphal S, Chung N et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. 9(4), 575–584 (2007).
   Google Scholar
• Farnier M, Averna M, Missault L et al. Lipid‑altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high‑risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – The IN‑CROSS study. Int. J. Clin. Pract. 63(4), 547–559 (2009).
   Google Scholar
• Hing Ling PK, Civeira F, Dan AG et al. Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double‑blind, active‑controlled, multicenter study. Lipids Health Dis. 11, 18 (2012).
   Google Scholar
• Rosen JB, Jimenez JG, Pirags V et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid‑lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diab. Vasc. Dis. Res. doi: 10.1177/1479164112465212 (2013) (Epub ahead of print).
   Google Scholar
• Bays H. Ezetimibe. Expert Opin. Investig. Drugs 11(11), 1587–1604 (2002).
   Google Scholar
• Morrone D, Weintraub WS, Toth PP et al. Lipid‑altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 223(2), 251–261 (2012). ▪▪ Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy in a pooled analysis of 27 clinical studies across diverse patient populations.
   Google Scholar
• Zieve F, Brown WV, Foody JM et al. Attainment of dual treatment levels for hsCRP and lipids in older (=65) patients with CVD risk: ezetimibe/simvastatin vs atorvastatin. J. Clin. Lipidol. 5, 3 (2010).
   Google Scholar
• Ben Yehuda O, Wenger NK, Constance C et al. The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years. J. Geriatr. Cardiol. 8(1), 1–11 (2011).
   Google Scholar
• Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low‑density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double‑blind, placebo‑controlled trial. Am. J. Geriatr. Pharmacother. 3(4), 218–228 (2005).
   Google Scholar
• Bays HE, Conard SE, Leiter LA, Bird SR, Lowe RS, Tershakovec AM. Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin uptitration in patients at moderately high or high risk for coronary heart disease. Int. J. Cardiol. 153(2), 141–147 (2011).
   Google Scholar
• Robinson JG, Davidson MH, Shah A et al. Efficacy and safety of ezetimibe and ezetimibe+statin therapy in patients aged <65, 65–74, and 75 years and older. Aging Health 3(6), 691–705 (2007).
   Google Scholar
• Lipka L, Sager P, Strony J, Yang B, Suresh R, Veltri E. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 21(15), 1025–1032 (2004).
   Google Scholar
• Abramson BL, Benlian P, Hanson ME, Lin J, Shah A, Tershakovec AM. Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients. Lipids Health Dis. 10, 146 (2011). ▪ Describes the lipid responses to ezetimibe plus statin and statin therapies in women and men using data from 27 pooled studies.
   Google Scholar
• Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. J. Womens Health (Larchmt) 13(10), 1101–1107 (2004).
   Google Scholar
• Ose L, Shah A, Davies MJ et al. Consistency of lipid‑altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr. Med. Res. Opin. 22(5), 823–835 (2006).
   Google Scholar
• Davidson MH, Ballantyne CM, Kerzner B et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo‑controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. 58(8), 746–755 (2004).
   Google Scholar
• Pearson TA, Denke MA, McBride PE et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low‑density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the ezetimibe add‑on to statin for effectiveness trial. Mayo Clin. Proc. 81(9), 1177–1185 (2006).
   Google Scholar
• Goldberg RB, Guyton JR, Mazzone T et al. Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with Type 2 diabetes and hypercholesterolemia. Diabetes Care 33(5), 1021–1024 (2010).
   Google Scholar
• Weinstock RS, Goldberg RB, Guyton JR et al. Effect of ezetimibe/simvastatin on lowering levels of LDL‑C and non‑HDL‑C, apoB, and hs‑CRP in patients with Type 2 diabetes. J. Clin. Lipidol. 2(1), 25–35 (2008).
   Google Scholar
• Abate N, Catapano AL, Ballantyne CM et al. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analyses. J. Clin. Lipidol. 2(2), 91–105 (2008).
   Google Scholar
• Conard S, Bays H, Leiter LA et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes. Metab. 12(3), 210–218 (2010).
   Google Scholar
• Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL‑C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab. Vasc. Dis. Res. 3(2), 93–102 (2006).
   Google Scholar
• Simons L, Tonkon M, Masana L et al. Effects of ezetimibe added to on‑going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr. Med. Res. Opin. 20(9), 1437–1445 (2004).
   Google Scholar
• Leiter LA, Betteridge DJ, Farnier M et al. Lipid‑altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes. Metab. 13(7), 615–628 (2011). ▪ Evaluates the lipid-altering effect of combination ezetimibe plus statin therapy versus statin monotherapy, and safety in Type 2 diabetes mellitus patients.
   Google Scholar
• Guyton JR, Betteridge DJ, Farnier M et al. Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diab. Vasc. Dis. Res. 8(2), 160–172 (2011). ▪ Pooled analysis of 27 studies evaluating the effect of ezetimibe plus statins versus statins on lipid goals in Type 2 diabetes mellitus patients.
   Google Scholar
• Averna M, Missault L, Vaverkova H et al. Lipid‑altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high‑risk patients with and without metabolic syndrome. Diab. Vasc. Dis. Res. 8(4), 262–270 (2011).
   Google Scholar
• Feldman T, Ose L, Shah A et al. Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome. Metab. Syndr. Relat. Disord. 5(1) 13–21 (2007).
   Google Scholar
• Robinson JG, Ballantyne CM, Hsueh W et al. Achievement of specified low‑density lipoprotein cholesterol, non‑high‑density lipoprotein cholesterol apolipoprotein B, and high‑sensitivity C‑reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J. Clin. Lipidol. 5(6), 474–482 (2011).
   Google Scholar
• Farnier M, Freeman MW, MacDonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26(9), 897–905 (2005).
   Google Scholar
• Fazio S, Guyton JR, Polis AB et al. Longterm safety and efficacy of triple combination ezetimibe/simvastatin plus extended‑release niacin in patients with hyperlipidemia. Am. J. Cardiol. 105(4), 487–494 (2010).
   Google Scholar
• Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid‑altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‑release niacin in patients with type IIa or type IIb hyperlipidemia. J. Am. Coll. Cardiol. 51(16), 1564–1572 (2008).
   Google Scholar
• McKenney JM, Farnier M, Lo KW et al. Safety and efficacy of long‑term co‑administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. 47(8), 1584–1587 (2006).
   Google Scholar
• Xydakis AM, Guyton JR, Chiou P, Stein JL, Jones PH, Ballantyne CM. Effectiveness and tolerability of ezetimibe add‑on therapy to a bile acid resin‑based regimen for hypercholesterolemia. Am. J. Cardiol. 94(6), 795–797 (2004).
   Google Scholar
• Zema MJ. Add‑on therapy for hypercholesterolemia: a pilot comparison of two gastrointestinally‑acting agents in statin‑treated patients. J. Clin. Lipidol. 3(2), 119–124 (2009).
   Google Scholar
• Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105(21), 2469–2475 (2002).
   Google Scholar
• Yamamoto A, Harada‑Shiba M, Endo M et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL‑apheresis therapy. Atherosclerosis 186(1), 126–131 (2006).
   Google Scholar
• van der Graaf, Cuffie‑Jackson C, Vissers MN et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. 52(17), 1421–1429 (2008).
   Google Scholar
• Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358(14), 1431–1443 (2008).
   Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double‑blind trial. Lancet 357(9256), 577–581 (2001).
   Google Scholar
• Stein EA. Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima–media thickness: more clarity or confusion? J. Am. Coll. Cardiol. 52(25), 2206–2209 (2008).
   Google Scholar
• Toth PP , Maki KC. A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) trial: should ezetimibe move to the “back of the line” as a therapy for dyslipidemia? J. Clin. Lipidol. 2(5), 313–317 (2008). ▪ Commentary on the ENHANCE trial results in the context of other carotid intima–media thickening studies.
   Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356(16), 1620–1630 (2007).
   Google Scholar
• Simon T, Boutouyrie P, Gompel A et al. Rationale, design and methods of the CASHMERE study. Fundam. Clin. Pharmacol. 18(1), 131–138 (2004).
   Google Scholar
• van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long‑term safety and efficacy of high‑dose atorvastatin treatment in patients with familial hypercholesterolemia. Am. J. Cardiol. 95(2), 264–266 (2005).
   Google Scholar
• Fleg JL, Mete M, Howard BV et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in Type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 52(25), 2198–2205 (2008). ▪ Substudy of the SANDS trial that compared the effect of ezetimibe plus statin with statins on carotid intima–media thickening.
   Google Scholar
• Califf RM, Lokhnygina Y, Cannon CP et al. An update on the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‑IT) design. Am. Heart J. 159(5), 705–709 (2010). ▪ Update on the ongoing IMPROVE-IT trial evaluating the effect of ezetimibe plus simvastatin versus simvastatin on CVD events.
   Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563–1574 (2010). ▪ Assessed the effect of combination fibrate plus statin therapy versus statin monotherapy on CVD risk in patients with Type 2 diabetes mellitus at high CVD risk.
   Google Scholar
• Costanzo P, Perrone‑Filardi P, Vassallo E et al. Does carotid intima–media thickness regression predict reduction of cardiovascular events? A meta‑analysis of 41 randomized trials. J. Am. Coll. Cardiol. 56(24), 2006–2020 (2010).
   Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended‑release niacin or ezetimibe and carotid intima–media thickness. N. Engl. J. Med. 361(22), 2113–2122 (2009).
   Google Scholar
• Duivenvoorden R, Vergeer M, Kastelein JJ. Niacin compared with ezetimibe. N. Engl. J. Med. 362(11), 1046–1047 (2010).
   Google Scholar
• Salen G, von Bergmann K, Lutjohann D et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109(8), 966–971 (2004).
   Google Scholar
• Lutjohann D, von Bergmann K, Sirah W et al. Long‑term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2‑year, open‑label extension study. Int. J. Clin. Pract. 62(10), 1499–1510 (2008).
   Google Scholar
• Salen G, Starc T, Sisk CM, Patel SB. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 130(6), 1853–1857 (2006).
   Google Scholar
• Baigent C , Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int. Suppl. 84, S207–S210 (2003).
   Google Scholar
• Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. Lancet 377(9784), 2181–2192 (2011). ▪▪ SHARP trial results comparing the effect of ezetimibe plus statin therapy versus placebo in patients with chronic kidney disease.
   Google Scholar
• SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‑density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 160(5), 785–794 (2010).
   Google Scholar
• Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360(14), 1395–1407 (2009).
   Google Scholar
• Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353(3), 238–248 (2005).
   Google Scholar
• Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo‑controlled trial. Lancet 361(9374), 2024–2031 (2003).
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta‑analysis of indivudual data from 27 randomised trials. Lancet 380(9841), 581–590 (2012).
   Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol‑lowering with simvastatin in 5963 people with diabetes: a randomised placebo‑controlled trial. Lancet 361(9374), 2005–2016 (2003).
   Google Scholar
• Navaneethan SD, Pansini F, Perkovic V et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst. Rev. 2, CD007784 (2009).
   Google Scholar
• Strippoli GF, Navaneethan SD, Johnson DW et al. Effects of statins in patients with chronic kidney disease: meta‑analysis and meta‑regression of randomised controlled trials. BMJ 336(7645), 645–651 (2008).
   Google Scholar
• Tonelli M, Keech A, Shepherd J et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J. Am. Soc. Nephrol. 16(12), 3748–3754 (2005).
   Google Scholar
• Holme I, Boman K, Brudi P et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am. J. Cardiol. 105(12), 1802–1808 (2010). ▪ Substudy of the SEAS trial that assessed the relationship between lipid lowering and ischemic cardiovascular events.
   Google Scholar
• Cannon CP, Guigliano RP, Blazing MA et al. Design and Rationale of IMPROVE‑IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome. Am. Heart J. 156(5), 826–832 (2008).
   Google Scholar
• Toth PP, Morrone D, Weintraub WS et al. Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6–24 weeks. Int. J. Clin. Pract. 66(8), 800–812 (2012). ▪▪ Analysis of ezetimibe plus statin safety data from 27 pooled clinical trials.
   Google Scholar
• Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM. Review of side‑effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am. J. Cardiol. 101(11), 1606–1613 (2008).
   Google Scholar
• Derosa G, D’Angelo A, Franzetti IG et al. Efficacy and safety of ezetimibe/simvastatin association on non‑diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J. Clin. Pharm. Ther. 34(3), 267–276 (2009).
   Google Scholar
• Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin‑induced myopathy – a genome wide study. N. Engl. J. Med. 359(8), 789–799 (2008).
   Google Scholar
• Peto R, Emberson J, Landray M et al. Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med. 359(13), 1357–1366 (2008). ▪▪ Meta-analysis of safety data in the ongoing IMPROVE-IT trial and the reported SHARP trial.
   Google Scholar
• Alsheikh‑Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post‑marketing analysis. J. Clin. Lipidol. 3(2), 138–142 (2009).
   Google Scholar
• Halleck M, Davis HR, Kirschmeier P et al. An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight‑of‑evidence approach. Toxicology 258(2–3), 116–130 (2009).
   Google Scholar